| Literature DB >> 33634362 |
Morteza Saberi1, Xiaolei Zhang2,3, Ali Mobasheri4,5,6,7.
Abstract
The prevalence of rheumatic and musculoskeletal diseases (RMDs) including osteoarthritis (OA) and low back pain (LBP) in aging societies present significant cost burdens to health and social care systems. Intervertebral disc (IVD) degeneration, which is characterized by disc dehydration, anatomical alterations, and extensive changes in extracellular matrix (ECM) composition, is an important contributor to LBP. IVD cell homeostasis can be disrupted by mitochondrial dysfunction. Mitochondria are the main source of energy supply in IVD cells and a major contributor to the production of reactive oxygen species (ROS). Therefore, mitochondria represent a double-edged sword in IVD cells. Mitochondrial dysfunction results in oxidative stress, cell death, and premature cell senescence, which are all implicated in IVD degeneration. Considering the importance of optimal mitochondrial function for the preservation of IVD cell homeostasis, extensive studies have been done in recent years to evaluate the efficacy of small molecules targeting mitochondrial dysfunction. In this article, we review the pathogenesis of mitochondrial dysfunction, aiming to highlight the role of small molecules and a selected number of biological growth factors that regulate mitochondrial function and maintain IVD cell homeostasis. Furthermore, molecules that target mitochondria and their mechanisms of action and potential for IVD regeneration are identified. Finally, we discuss mitophagy as a key mediator of many cellular events and the small molecules regulating its function.Entities:
Keywords: Degeneration; Growth factor; Intervertebral disc (IVD); Mitochondrial dysfunction; Mitophagy; Small molecule; Therapeutic
Mesh:
Year: 2021 PMID: 33634362 PMCID: PMC8110620 DOI: 10.1007/s11357-021-00341-1
Source DB: PubMed Journal: Geroscience ISSN: 2509-2723 Impact factor: 7.713
Fig. 1Consequences of intervertebral disc degeneration. The interplay between mitochondrial dysfunction, oxidative stress, and inflammation
Fig. 2Mitochondria-targeted anti-oxidants using TPP+ and hemigracidin S as moieties highly accumulate in mitochondria relative to unmodified anti-oxidants
Small molecules targeting mitochondrial dysfunction in IVD cells and their biological consequences
| Compound (molecular weight, g/mol) | Conditioning method | Biological consequences | References |
|---|---|---|---|
| Curcumin (368.38) | TBHP-treated NP cells | ∆ | [ |
| Resveratrol (228.25) | Sodium nitroprusside-induced NP cells | Decreased intracellular ROS, ∆ | [ |
| ∆ | [ | ||
| Autophagy induction via PI3K/Akt signaling pathway, anti-degenerative | [ | ||
| Polydatin (390.4) | TNF-α-treated NP cells, AF-punctured rat model | Inhibited cell senescence, activated Nrf2 both in vitro and in vivo, preserved ECM homeostasis, and alleviated IVD degeneration | [ |
| H2O2-treated EPC | ∆ | [ | |
| Naringin (580.5) | H2O2-treated NPMSCs | ∆ | [ |
| Icariin (676.7) | H2O2-treated NP cells AF-punctured rat model | Activated Nrf2 and upregulated Nrf1 and TFAM, inhibited cytochrome C release from mitochondria, and apoptosis ameliorated IVD degeneration via Nrf2 upregulation | [ |
| EGCC (458.4) | H2O2-treated IVD cells | ∆ | [ |
| NAC (163.2) | Mechanical-loaded NP cells | Downregulated P53 and 16 expressions and inhibited senescence | [ |
| Hyper-osmolality-treated NP cells | Decreased intracellular ROS, and inhibited senescence | [ | |
| Melatonin (232.28) | TBHP-treated EPC, AF-punctured rat model | Sirtuin 1 activation, inhibited EPC calcification | [ |
| H2O2-treated NP cells | Inhibited mitochondrial injury by ∆ | [ | |
| TBHP-treated NP cells, AF-punctured rat model | Anti-apoptotic, preserved ECM homeostasis via mitophagy induction both in vitro and in vivo | [ | |
| IL-1β-treated NP cells | Attenuated NLRP3 inflammasome activation, decreased mtROS level | [ | |
| ALA (206.3) | High-glucose-treated EPC | Decreased ROS level, inhibited mitochondria-mediated apoptosis, ∆ | [ |
| MitoQ (678.8) | Compression-loaded NP cells | Activated Nrf2 and upregulated downstream genes, SOD2 and NQO-1, regulated mitochondrial dynamic molecules, upregulation of Mfn1 and 2, and downregulation of Drp1, ∆ | [ |
| MitoTEMPO (511) | AGE-treated NP cells | Alleviated mitochondrial membrane transition pore opening, decreased mtROS level, anti-apoptosis, ∆ | [ |
| SkQ1 (617.6) | AGE-treated NP cells | Alleviated mitochondrial membrane transition pore opening, decreased mtROS level, anti-apoptosis | [ |
| XJB-5-131 (959.2) | Accelerated aging ERCC1−/∆ mouse model | Ameliorated IVD degeneration, enhanced disc ECM content | [ |
Fig. 3Mitophagy pathways and regulatory small molecules for IVD cells: mitophagy in IVD cells takes place via two pathways: (i) Parkin-dependent: salidroside and FCCP as mitophagy activators enhance parkin level. Salidroside also downregulates P62 expression. Mito Q facilitates P62 degradation and leads to lysosomal digestion. (ii) Parkin independent: SP600125 (JNK inhibitor) inhibits JNK phosphorylation and LC3-II accumulation in oxidative stress-induced bone marrow-derived mesenchymal stem cells. Honokiol upregulates mitochondria dynamic molecules, Mfn-2 and Drp-1, expression, and activates the mitophagy receptor, BNIP3. Bafilomycin A1 inhibits lysosomal degradation of autophagosome and LC3-II accumulation. A PINK-1 phosphorylation and parkin ubiquitination, B, E mitophagy receptors activation, C, F autophagosome formation, D lysosomal digestion
Mitophagy activators and their mechanism of action in IVD cells
| Small molecule (molecular weight, g/mol) | Concentration | Therapeutic target (molecule/signaling pathway) | Therapeutic outcome | Reference |
|---|---|---|---|---|
| MitoQ (678.8) | 200–500 nM | PINK1/parkin activation | Repair of impaired mitophagy (P62↓) | [ |
| Honokiol (266.3) | < 10 μM | AMPK/PGC-1α/sirtuin 3 activation | Anti-oxidant activity (SOD)↑ | [ |
| Cell senescence↓ | ||||
| Salidroside (300.3) | 200 μM | Parkin activation | Repair of impaired mitophagy (P62↓) | [ |
| Urolithin A (228.2) | 0–20 μM | AMPK activation | Apoptosis↓, ∆ | [ |